Comment on 'Impact of UK Medical Eligibility Criteria implementation on prescribing of combined hormonal contraceptives': author's response
PaulaBriggs, ,
May 13, 2016
On behalf of all the authors I would like to thank Sarah Holden for
her comments[1] on our recently published article.[2]
When designing the study, we recognised that the majority of women
receive their contraception from their general practitioner (GP). Our
study compares the prescribing habits of GPs in 2005 pre-UK Medical
Eligibility Criteria (pre-UKMEC) to those in 2010 (post-UKMEC).
Whilst the authors realise that this does not reflect total
contraceptive usage in the UK, it does compare women prescribed combined
hormonal contraceptives (CHCs) by their GPs in 2005 to a similar group of
women in 2010. Consequently we presume that we are comparing 'apples' with
'apples' and therefore our conclusion that there was "a reduction in
prescribing of CHCs to higher-risk women after publication of UKMEC, a
large number of women with Category 3 or 4 risk factors are still
prescribed CHCs" is valid and is worth publicising to the reproductive
health clinical community.
References
1. Holden SE. Comment on 'Impact of UK Medical Eligibility Criteria
implementation on prescribing of combined hormonal contraceptives'. J Fam
Plann Reprod Health Care 2013;00:1. doi:10.1136/jfprhc-2013-100627.
2. Briggs PE, Praet CA, Humphreys SC, et al. Impact of UK Medical
Eligibility Criteria implementation on prescribing of combined hormonal
contraceptives. J Fam Plann Reprod Health Care 2013;39:1-7. Published
Online First 7 January 2013. doi:10.1136/jfprhc-2012-100376.
On behalf of all the authors I would like to thank Sarah Holden for her comments[1] on our recently published article.[2]
When designing the study, we recognised that the majority of women receive their contraception from their general practitioner (GP). Our study compares the prescribing habits of GPs in 2005 pre-UK Medical Eligibility Criteria (pre-UKMEC) to those in 2010 (post-UKMEC).
Whilst the authors realise that this does not reflect total contraceptive usage in the UK, it does compare women prescribed combined hormonal contraceptives (CHCs) by their GPs in 2005 to a similar group of women in 2010. Consequently we presume that we are comparing 'apples' with 'apples' and therefore our conclusion that there was "a reduction in prescribing of CHCs to higher-risk women after publication of UKMEC, a large number of women with Category 3 or 4 risk factors are still prescribed CHCs" is valid and is worth publicising to the reproductive health clinical community.
References
1. Holden SE. Comment on 'Impact of UK Medical Eligibility Criteria implementation on prescribing of combined hormonal contraceptives'. J Fam Plann Reprod Health Care 2013;00:1. doi:10.1136/jfprhc-2013-100627.
2. Briggs PE, Praet CA, Humphreys SC, et al. Impact of UK Medical Eligibility Criteria implementation on prescribing of combined hormonal contraceptives. J Fam Plann Reprod Health Care 2013;39:1-7. Published Online First 7 January 2013. doi:10.1136/jfprhc-2012-100376.
Conflict of Interest:
None declared